<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02762214</url>
  </required_header>
  <id_info>
    <org_study_id>RoManHy</org_study_id>
    <nct_id>NCT02762214</nct_id>
  </id_info>
  <brief_title>Role of Uterine Manipulator in Hysterectomy - Ro.Man.HY</brief_title>
  <acronym>RoManHy</acronym>
  <official_title>Role Of Uterine Manipulator in Hysterectomy for Early Stage Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective multicentric randomized trial to evaluate the role of uterine manipulator on
      laparoscopic/robotic total hysterectomy for the treatment of early stage G1 - G2 endometrial
      cancer (International Federation of Gynecology and Obstetrics - FIGO stages IA-IB).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicentric prospective randomized Phase III trial is aimed to verify if the use of
      uterine manipulator for laparoscopic/robotic treatment of early stage endometrial cancer can
      influence the impact of peritoneal cytology and lymph vascular space invasion (LVSI) and the
      outcomes in terms of perioperative and oncological (disease free survival - DFS, overall
      survival - OS) outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Upstaging rate</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluation of Lymphovascular space invasion and pre- / post-Hysterectomy pelvic cytology in order to investigate if the use of uterine manipulator has a role in upstaging of early-stage endometrial cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>within 30 days from surgery</time_frame>
    <description>To measure intra- and postoperative complication rate in order to investigate the specific role of uterine manipulator in complication occurred during hysterectomy or within 30 days after.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Loss</measure>
    <time_frame>Intraoperative</time_frame>
    <description>To measure intraoperative estimated blood loss (EBL) in order to investigate the specific role of uterine manipulator in hemostatic control during Hysterectomy safety of laparoscopic hysterectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of surgical procedure</measure>
    <time_frame>Perioperative</time_frame>
    <description>To measure the specific role of uterine manipulator in impact on surgery. More in dept operative time (OT), ileus, discharge time will be respectively measured in minutes, hours and days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of uterine manipulator in Obesity</measure>
    <time_frame>Intraoperative</time_frame>
    <description>To determine the specific correlations between the use or not of uterine manipulator and Body Mass Index (BMI measured in kg/m2). To investigate if even this issue could influence the intraoperative safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on postoperative pain</measure>
    <time_frame>Postoperative</time_frame>
    <description>To investigate if the use or not of uterine manipulator could have a role in postoperative pain. Visual Analog Score (VAS) will be used to evaluate it.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncological Outcomes: Rate of local relapses</measure>
    <time_frame>1 years - 5 years</time_frame>
    <description>To investigate if the use or not of uterine manipulator could determine an higher rate of local relapses</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>With Uterine Manipulator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>77 Patients affected by early stage endometrial cancer submitted to elective laparoscopic/robotic hysterectomy for endometrial cancer using uterine manipulator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without Uterine Manipulator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>77 Patients affected by early stage endometrial cancer submitted to elective laparoscopic/robotic hysterectomy for endometrial cancer without support of uterine manipulator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clermont-Ferrand Uterine Manipulator</intervention_name>
    <description>Pelvic cytology is obtained before starting surgical procedures (washing number 1).
After tubal coagulation, Clermont-Ferrand Uterine Manipulator is installed inside the uterus. At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)</description>
    <arm_group_label>With Uterine Manipulator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No uterine Manipulator</intervention_name>
    <description>Pelvic cytology is obtained before starting surgical procedures (washing number 1). None uterine manipulator is used and the cervix is closed with a cross stitch.
Tubal coagulation, At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)</description>
    <arm_group_label>Without Uterine Manipulator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For patients

          -  Age &gt; 18 &lt; 80 years

          -  Patient's informed consent

          -  American Society of Anesthesiologists: &lt; class III or IV

          -  No actual pregnancies

          -  Body Mass Index (BMI) â‰¤ 35

        For diseases

          -  Early stage endometrial cancer (IA-IB)

          -  Endometrioid histotype (G1-G2)

        Exclusion Criteria:

        For patients

          -  Age &gt; 18 &lt; 80

          -  Actual pregnancies

          -  Previous gynecological cancer

        For disease

          -  Type II endometrial cancer histotype

          -  Grade 3 endometrial cancer

          -  Advanced stage endometrial cancer (II - IV)

          -  Previous radiotherapy on the pelvic field

          -  Uterine size larger than conform 12 weeks gestation or 9 cm in horizontal

          -  Necessity of laparotomic procedures
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Oncologic Gynecology, Fondazione Policlinico Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Gueli Alletti</last_name>
      <phone>+390630158545</phone>
      <email>salvatore.guelialletti@policlinicogemelli.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Scambia, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salvatore Gueli Alletti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Fagotti, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Fanfani, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefano Cianci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gian Franco Zannoni, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2016</study_first_submitted>
  <study_first_submitted_qc>May 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Prof. Giovanni Scambia</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Uterin manipulator</keyword>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Laparoscopy</keyword>
  <keyword>Robotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

